Unicycive Therapeutics, Inc. (UNCY)
| Market Cap | 75.42M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -31.50M |
| Shares Out | 17.66M |
| EPS (ttm) | -2.90 |
| PE Ratio | n/a |
| Forward PE | 2.03 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 228,707 |
| Open | 4.250 |
| Previous Close | 4.250 |
| Day's Range | 4.210 - 4.314 |
| 52-Week Range | 2.833 - 11.000 |
| Beta | 1.87 |
| Analysts | Strong Buy |
| Price Target | 63.75 (+1,392.97%) |
| Earnings Date | Aug 14, 2025 |
About UNCY
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb RZB 012 for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company also evaluates licensing of technologies and drugs for orphan diseases, other renal, liver, and other metabolic diseases affecting fibros... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for UNCY stock is "Strong Buy." The 12-month stock price target is $63.75, which is an increase of 1,392.97% from the latest price.
News
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive Therapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their Options If you purchased or acquir...
Unicycive Therapeutics to Participate in Upcoming Investor Events in September
LOS ALTOS, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Com...
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive Therapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their Options
Shareholders who lost money in shares of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Should Contact Wolf Haldenstein Immediately.
Lead Plaintiff Deadline is October 14, 2025 NEW YORK , Aug. 21, 2025 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the U...
Shareholders who lost money in shares of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Should Contact Wolf Haldenstein Immediately
New York, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Northe...
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive Therapeutics
NEW YORK--(BUSINESS WIRE)---- $UNCY #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Unicycive Therapeutics, Inc. (“Unicycive” or t...
Unicycive Therapeutics Granted New U.S. Patent for UNI-494 to Treat Chronic Kidney Disease
LOS ALTOS, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Com...
Unicycive Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm
Investors can contact the law firm at no cost to learn more about recovering their losses
Unicycive Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update
- Type A Meeting requested with U.S. Food and Drug Administration (FDA) for resolution of the Complete Response Letter (CRL) for oxylanthanum carbonate (OLC) - OLC pivotal study data, published in the...
Unicycive Therapeutics: Manageable CMC Speed-Bump--Pill-Burden Edge Intact, Buying
Initiating coverage on Unicycive Therapeutics, Inc. with a Buy rating and $6 price target, as the recent FDA CRL is manufacturing-related and resolvable. OLC's ultra-low pill burden and strong patient...
Unicycive Therapeutics Announces the Publication of Oxylanthanum Carbonate Pivotal Trial Data in Clinical Journal of the American Society of Nephrology
LOS ALTOS, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Com...
UNCY Investors Have Opportunity to Join Unicycive Therapeutics, Inc. Fraud Investigation With the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $UNCY--UNCY Investors Have Opportunity to Join Unicycive Therapeutics, Inc. Fraud Investigation with the Schall Law Firm.
Unicycive Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
LOS ALTOS, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patient...
Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference
LOS ALTOS, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patient...
Unicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
--Complete Response Letter (CRL) cited deficiencies previously identified at a third-party manufacturing vendor unrelated to Oxylanthanum Carbonate (OLC)
Unicycive Therapeutics, Inc. Announces Reverse Stock Split
Shares Expected to Begin Trading on Split-Adjusted Basis on June 20, 2025 Shares Expected to Begin Trading on Split-Adjusted Basis on June 20, 2025
Unicycive Provides Update on New Drug Application for Oxylanthanum Carbonate to Treat Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
- The U.S. Food and Drug Administration (FDA) identified deficiencies at a third-party manufacturing vendor - FDA to provide final decision by PDUFA action date of June 28, 2025 LOS ALTOS, Calif., Jun...
Unicycive Therapeutics to Present at Upcoming Investor Conferences
LOS ALTOS, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today ann...
Unicycive Therapeutics Announces Time Change for 2025 Annual Meeting of Stockholders
LOS ALTOS, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ: UNCY) (“Unicycive” or the “Company”), a clinical stage biotechnology company developing therapies for patients...
Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update
- Oxylanthanum carbonate (OLC) New Drug Application (NDA) for hyperphosphatemia in chronic kidney disease patients on dialysis under review by FDA with PDUFA target action date of June 28, 2025; ongoi...
Unicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
LOS ALTOS, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today a...
Unicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business Update
- Oxylanthanum carbonate (OLC) New Drug Application for hyperphosphatemia in chronic kidney disease patients on dialysis under review by the FDA with a PDUFA target action date of June 28, 2025 - Comm...
Unicycive to Highlight Patient Reported Outcomes Data at Upcoming Medical Meetings Showing Oxylanthanum Carbonate Reduced Pill Burden and Improved Adherence in Treatment of Hyperphosphatemia
LOS ALTOS, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today a...
Unicycive Therapeutics Announces the Publication of Preclinical Data on Synergies Between Oxylanthanum Carbonate and Tenapanor in American Society of Nephrology Journal Kidney360
LOS ALTOS, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today an...
Unicycive Therapeutics Announces the Publication of Patient Perspectives on Phosphate Management in the Journal of Nephrological Science
Large pill size, high pill burden and palatability were identified as key barriers for phosphate binder adherence Large pill size, high pill burden and palatability were identified as key barriers for...